The PolyNovo Ltd (ASX: PNV) share price is on the rise on Wednesday morning.
At the time of writing, the medical device company’s shares are up 13% to $1.22.
Why is the PolyNovo share price on the move?
Investors have been bidding the PolyNovo share price higher following the release of a third quarter update.
According to the release, PolyNovo delivered unaudited revenue of A$12.26 million during the third quarter of FY 2022. This represents a 59.3% increase on the revenue of A$7.69 million reported during the prior corresponding period.
This reflects a 79.4% increase in US sales to a record US$6.89 million (A$9.53 million) and an 81.9% lift in ANZ sales to A$1.16 million. It also includes income of A$1 million relating to BARDA and A$0.1 million from a Victorian State Government grant.
This means that PolyNovo’s year to date revenue is now A$30.4 million, which implies an annual run rate of A$48 million.
PolyNovo’s Chair, David Williams, explained that this result was driven by an increase in its salesforce and easing COVID-19 headwinds.
He said “More sales reps equals a wider geographical footprint and increased sales. More reps and the diminishing effects of Covid, have driven record sales in US, UKI and Australia.”
What else?
One thing that has been weighing on the PolyNovo share price this year has been concerns over its dwindling cash balance and the potential requirement of a capital raising in the near future.
Positively, the heavily shorted company’s cash balance increased during the third quarter even before taking into account the sale of its Lorimer Street property.
At the end of March, PolyNovo had cash of A$3.8 million, which was up A$0.5 million since the end of December. This will soon be boosted by a further A$6.35 million from the Lorimer Street property sale when the process completes in June.
Finally, management advised that its clinical trial programmes remain on track. This includes recruitment for the pivotal burn trial and enrolment of the first patients for the DFU trial.
PolyNovo is also on track to file for the 510K approval for the Matrix product during this financial year and work on the prototypes for Hernia development and new designs for BTM are also on track.
The post Why is the PolyNovo share price surging 13% higher today? appeared first on The Motley Fool Australia.
Should you invest $1,000 in PolyNovo right now?
Before you consider PolyNovo, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and PolyNovo wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of January 13th 2022
More reading
- These are the 10 most shorted ASX shares
- What’s driving the Polynovo (ASX:PNV) share price higher today?
- These are the 10 most shorted ASX shares
- Polynovo (ASX:PNV) share price spikes 7% as healthcare stages comeback rally
- These are the 10 most shorted ASX shares
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns and has recommended POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/f9HNSbg
Leave a Reply